Clinical Trials in Georgia: The Caucasus Hidden Gem

Wedged between the Greater Caucasus mountains to the north and the Black Sea to the west, Georgia occupies one of the world's most dramatic geographic positions; a land bridge between Eastern Europe and Western Asia, sharing borders with Russia, Turkey, Armenia, and Azerbaijan. Its 69,700 km² encompass extraordinary diversity: alpine meadows, Black Sea coastline, semi-arid plains, and ancient wine valleys that claim among the oldest winemaking traditions on earth.

Tbilisi, the capital, is home to roughly 1.2 million of the country's 3.7 million people and is the undisputed center of its medical and research infrastructure. Georgia declared independence from the Soviet Union in 1991 and has since undergone one of the more striking economic and governance transformations in the post-Soviet world; earning the label "star reformer" from the World Bank in 2018. In December 2023, the European Commission granted Georgia EU candidate status, further aligning its regulatory frameworks with European standards.

Georgia's population of approximately 3.7 million includes a predominantly ethnic Georgian majority alongside meaningful minority communities; Armenians, Azerbaijanis, Russians, Ossetians, and others; contributing to genetic and ethnic diversity that holds real value for clinical research. Life expectancy at birth stands at 72 years, and 6.1% of the population is over 69.

The country follows an aging demographic pattern common across the South Caucasus, with a low birth rate and urban concentration in Tbilisi and Batumi. A significant rural population, with limited prior exposure to novel therapeutics, represents a substantial pool of treatment-naïve patients; one of Georgia's most consistently cited advantages for sponsors.